| NCT06419205 | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G | WITHDRAWN | PHASE2 | 2024-06-27 | 2026-06 | 2026-06 |
| NCT06018428 | A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) | RECRUITING | PHASE2 | 2023-09-12 | 2026-09 | 2026-06 |
| NCT05509023 | Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-09-30 | 2024-12 | 2024-12 |
| NCT04485481 | Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers | COMPLETED | PHASE1 | 2020-09-08 | 2022-01-12 | 2022-01-12 |